乳腺癌新辅助化疗疗效的遗传学预测因子  

Predictive genetic biomakers of neoadjuvant chemotherapy in breast cancer

作　　者：王雯邈[1] 袁芃[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院肿瘤内科,北京100021

出　　处：《临床药物治疗杂志》2013年第3期28-32,53,共6页Clinical Medication Journal

摘　　要：乳腺癌的新辅助化疗(NCT)对于局部晚期的乳腺癌患者尤为重要。部分达到病理完全缓解(pCR)的患者可提高远期预后。但目前治疗中可达到pCR的患者仍不足25%,使得筛选出可用于预测NCT疗效的独立预测因子成为临床亟待解决的难题。本文系统回顾了有关局部晚期乳腺癌患者NCT疗效遗传学预测因子的文献,并讨论其未来用以指导临床个体化治疗的可行性及可靠性。Neoadjuvant chemotherapy takes an important role in patients with the locally advanced breast cancer. The pCR patients can have better prognosis. However, proportion of patients achieved pCR remains less than 25%, which makes it more important to screen predictive factors for evaluating neoadjuvant chemotherapy. In the present article, we summarize current knowledge about genetic biomarkers which have been demonstrated to have predictive value and discuss their future.

关 键 词：乳腺癌 新辅助化疗 疗效 遗传学 

分 类 号：R737.9[医药卫生—肿瘤] R969.3[医药卫生—临床医学]